Evelo Biosciences Inc. (EVLO) Prices 12M Share Common Offering at $3.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
After-Hours Movers 06/24: (ALLY) (BDN) (RPAI) Higher; (XERS) (QURE) (NK) Lower (more...)
June 24, 2020 5:46 PM EDTAfter-Hours Movers
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) 14.9% LOWER; announced that it has commenced concurrent underwritten public offerings of $20,000,000 in shares of its common stock (the Shares) and $60,000,000 aggregate principal amount of convertible senior notes due 2025 (the Notes).
uniQure N.V. (NASDAQ: QURE) 12.8% LOWER; announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQures investigational gene therapy for patients with hemophilia B. Etranacogene... More
UPDATE: Evelo Biosciences Inc. (EVLO) Announces Proposed $40M Common Share Offering
June 24, 2020 4:01 PM EDT(Updated - June 24, 2020 4:02 PM EDT)
Evelo Biosciences, Inc. (NASDAQ: EVLO) today announced that it intends to offer and sell, subject to market and other conditions, $40 million of its common stock in an underwritten public offering. Evelo expects to grant the underwriters a 30-day option, solely to cover over-allotments, if any, to... More
